| Literature DB >> 30104982 |
Gianni Biolo1, Filippo G Di Girolamo1, Adam McDonnell2, Nicola Fiotti1, Filippo Mearelli1, Roberta Situlin1, Arianna Gonelli3, Barbara Dapas4, Mauro Giordano5, Mitja Lainscak6, Gabriele Grassi4, Giorgio Zauli3, Paola Secchiero3, Igor Mekjavic2.
Abstract
In chronic diseases, hypoxia and physical inactivity are associated with atherosclerosis progression. In contrast, a lower mortality from coronary artery disease and stroke is observed in healthy humans residing at high altitude in hypoxic environments. Eleven young, male volunteers completed the following 10-day campaigns in a randomized order: hypoxic ambulatory, hypoxic bed rest and normoxic bed rest. Before intervention, subjects were evaluated in normoxic ambulatory condition. Normobaric hypoxia was achieved in a hypoxic facility simulating 4000 m of altitude. Following hypoxia, either in bed rest or ambulatory condition, markers of cardiometabolic risk shifted toward a more atherogenic pattern consisting of: (a) lower levels of total HDL cholesterol and HDL2 sub-fraction and decreased hepatic lipase; (b) activation of systemic inflammation, as determined by C-reactive protein and serum amyloid A; (c) increased plasma homocysteine; (d) decreased delta-5 desaturase index in cell membrane fatty acids, a marker of insulin sensitivity. Bed rest and hypoxia additively decreased total HDL and delta-5 desaturase index. In parallel to the pro-atherogenic effects, hypoxia activated selected anti-atherogenic pathways, consisting of increased circulating TNF-related apoptosis-inducing ligand (TRAIL), a protective factor against atherosclerosis, membrane omega-3 index and erythrocyte glutathione availability. Hypoxia mediated changes in TRAIL concentrations and redox glutathione capacity (i.e., GSH/GSSG ratio) were greater in ambulatory conditions (+34 ± 6% and +87 ± 31%, respectively) than in bed rest (+17 ± 7% and +2 ± 27% respectively). Hypoxia-induced cardiometabolic risk is blunted by moderate level of physical activity as compared to bed rest. TRAIL and glutathione redox capacity may contribute to the positive interaction between physical activity and hypoxia. Highlights: - Hypoxia and bed rest activate metabolic and inflammatory markers of atherogenesis. - Hypoxia and physical activity activate selected anti-atherogenic pathways. - Hypoxia and physical activity positive interaction involves TRAIL and glutathione.Entities:
Keywords: TRAIL; bed rest; glutathione; hypoxia; omega-3 fatty acids; oxidative stress
Year: 2018 PMID: 30104982 PMCID: PMC6077233 DOI: 10.3389/fphys.2018.01000
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Effects of hypoxia and bed rest on circulating insulin, inflammatory mediators, and TRAIL1.
| Ambulatory | Bed rest | ||||||
|---|---|---|---|---|---|---|---|
| Normoxia | Hypoxia | Normoxia | Hypoxia | Bed rest effect | Hypoxia effect | Interaction | |
| Insulin (μU⋅mL-1) | 7 ± 1 | 7 ± 1 | 7 ± 1 | 6 ± 1 | 0.85 | 0.93 | 0.27 |
| Glucose (mg⋅dL-1) | 94 ± 2 | 93 ± 1 | 93 ± 1 | 92 ± 1 | 0.35 | 0.57 | 1.00 |
| HOMA2-IR | 0.69 ± 0.01 | 0.68 ± 0.01 | 0.68 ± 0.01 | 0.67 ± 0.01 | 0.35 | 0.56 | 1.00 |
| Homocysteine (μmol × L-1) | 15.3 ± 1.7 | 17.0 ± 1.4 | 14.7 ± 1.4 | 16.2 ± 1.4 | 0.38 | 0.003 | 0.93 |
| C-reactive protein (mg⋅L-1) | 0.6 ± 0.1 | 1.7 ± 1.0 | 0.4 ± 0.1 | 0.8 ± 0.2 | 0.38 | 0.04 | 0.82 |
| Serum amyloid A (μg⋅L-1) | 19.6 ± 0.7 | 28.3 ± 3.0 | 22.9 ± 2.4 | 28.9 ± 3.6 | 0.26 | 0.03 | 0.59 |
| Presepsin (pg/ml) | 91 ± 8 | 70 ± 6* | 101 ± 13 | 107 ± 11 | 0.13 | 0.18 | 0.01 |
| TRAIL (pg/ml) | 80 ± 4 | 107 ± 7* | 82 ± 4 | 94 ± 5 | 0.21 | 0.001 | 0.01 |
Effects of hypoxia and bed rest on circulating lipids and enzyme involved in lipid metabolism.
| Ambulatory | Bed rest | ||||||
|---|---|---|---|---|---|---|---|
| Normoxia | Hypoxia | Normoxia | Hypoxia | Bed rest effect | Hypoxia effect | Interaction | |
| Total cholesterol (mg⋅dL-1) | 184 ± 13 | 173 ± 8 | 174 ± 10 | 180 ± 11 | 0.66 | 0.67 | 0.12 |
| LDL-C (mg⋅dL-1) | 117 ± 12 | 110 ± 7 | 110 ± 7 | 121 ± 9* | 0.17 | 0.18 | 0.01 |
| HDL-C (mg⋅dL-1) | 46 ± 10 | 33 ± 2 | 32 ± 2 | 28 ± 2 | <0.01 | 0.02 | 0.65 |
| HDL2-C (mg⋅dL-1) | 19 ± 9 | 9 ± 1 | 10 ± 1 | 7 ± 1 | 0.17 | 0.04 | 0.44 |
| HDL3-C (mg⋅dL-1) | 26 ± 2 | 24 ± 2 | 22 ± 2 | 21 ± 2 | 0.01 | 0.27 | 0.62 |
| HDL2-C/HDL3-C | 0.72 ± 0.28 | 0.41 ± 0.8 | 0.51 ± 0.09 | 0.33 ± 0.03 | 0.03 | 0.19 | 0.001 |
| Total/HDL cholesterol | 4.0 ± 0.5 | 4.4 ± 0.4 | 4.3 ± 0.3 | 4.8 ± 0.4 | <0.001 | <0.01 | 0.78 |
| Triglycerides (mg⋅dL-1) | 94 ± 14 | 113 ± 14 | 109 ± 20 | 102 ± 13 | 0.40 | 0.09 | 0.61 |
| Free fatty acid (μmol/L) | 286 ± 21 | 193 ± 28* | 205 ± 25 | 239 ± 26 | 0.35 | 0.17 | 0.02 |
| Cholesteryl ester transfer protein (μg⋅mL-1) | 2.81 ± 0.18 | 2.93 ± 0.18 | 2.96 ± 0.25 | 3.09 ± 0.16 | 0.32 | 0.31 | 0.95 |
| Lecithin-cholesterol acyltransferase (ng⋅L-1) | 21.8 ± 4.2 | 20.3 ± 4.3 | 21.7 ± 4.7 | 23.8 ± 6.3 | 0.66 | 0.99 | 0.45 |
| Lipoprotein lipase (ng⋅L-1) | 31.1 ± 3.3 | 24.5 ± 3.7 | 30.5 ± 4.8 | 25.8 ± 3.7 | 0.82 | 0.02 | 0.54 |
| Hepatic lipase (U⋅mL-1) | 0.72 ± 0.10 | 0.79 ± 0.09 | 0.80 ± 0.09 | 0.90 ± 0.08 | 0.15 | 0.04 | 0.81 |
| LPL-to-HL ratio | 56 ± 13 | 33 ± 5 | 39 ± 4 | 30 ± 5 | 0.15 | 0.03 | 0.31 |
Effects of hypoxia and bed rest on erythrocyte membranes fatty acid composition.
| Ambulatory | Bed rest | ||||||
|---|---|---|---|---|---|---|---|
| Normoxia | Hypoxia | Normoxia | Hypoxia | Bed rest effect | Hypoxia effect | Interaction | |
| Myristic 14:00 | 0.20 ± 0.02 | 0.31 ± 0.32 | 0.30 ± 0.03 | 0.25 ± 0.02 | 0.45 | 0.08 | 0.01 |
| Palmitic 16:00 | 20.6 ± 0.4 | 20.9 ± 0.3 | 20.6 ± 0.3 | 20.8 ± 0.3 | 0.71 | 0.15 | 0.76 |
| Stearic 18:00 | 18.5 ± 0.2 | 18.4 ± 0.1 | 18.6 ± 0.2 | 18.5 ± 0.1 | 0.58 | 0.27 | 9.64 |
| Palmitoleic 16:1 n7 | 0.25 ± 0.04 | 0.27 ± 0.04 | 0.28 ± 0.04 | 0.26 ± 0.03 | 0.72 | 1.00 | 0.26 |
| Oleic 18:1 n9 | 13.3 ± 0.3 | 12.8 ± 0.3 | 12.8 ± 0.3 | 12.9 ± 0.3 | 0.08 | 0.10 | 0.06 |
| Elaidic trans 18:1n-9 | 1.03 ± 0.04 | 1.02 ± 0.03 | 1.01 ± 0.05 | 1.05 ± 0.05 | 0.70 | 0.45 | 0.14 |
| Eicosenoic 20:1n-9 | 0.31 ± 0.01 | 0.3 ± 0.01 | 0.3 ± 0.01 | 0.31 ± 0.01 | 0.86 | 0.75 | 0.10 |
| Eicosapentaenoic 20:5 n-3 | 0.53 ± 0.04 | 0.58 ± 0.04 | 0.56 ± 0.03 | 0.54 ± 0.04 | 0.94 | 0.50 | 0.10 |
| Docosapentaenoic 22:5 n-3 | 2.50 ± 0.08 | 2.57 ± 0.10 | 2.55 ± 0.09 | 2.57 ± 0.09 | 0.43 | 0.02 | 0.41 |
| Docosahexaenoic 22:6 n-3 | 4.48 ± 0.23 | 4.69 ± 0.26 | 4.63 ± 0.25 | 4.80 ± 0.2 | 0.02 | 0.01 | 0.83 |
| Linoleic 18:2 n6 | 91.9 ± 0.35 | 11.7 ± 0.3 | 11.6 ± 0.35 | 11.39 ± 0.29 | 0.08 | 0.21 | 0.83 |
| Eicosadienoic 20:2 n-6 | 1.09 ± 0.51 | 1.47 ± 0.56 | 1.13 ± 0.19 | 0.89 ± 0.24 | 0.60 | 0.63 | 0.50 |
| Dihomo-γ-linolenic 20:3 n-6 | 1.97 ± 0.13 | 2.04 ± 0.13 | 2.08 ± 0.12 | 2.16 ± 0.13 | 0.001 | 0.02 | 0.98 |
| Arachidonic 20:4 n-6 | 18.1 ± 0.3 | 17.7 ± 0.3* | 18.2 ± 0.2 | 18.4 ± 0.3 | 0.04 | 0.49 | 0.02 |
| Adrenic 22:4 n-6 | 4.15 ± 0.20 | 3.99 ± 0.18 | 4.12 ± 0.17 | 4.17 ± 0.18 | 0.07 | 0.02 | 0.02 |
| Docosapentaenoic 22:5 n-6 | 0.99 ± 0.08 | 1.10 ± 0.13 | 1.17 ± 0.17 | 0.98 ± 0.08 | 0.71 | 0.47 | 0.17 |
| n-3 index1 | 5.01 ± 0.25 | 5.27 ± 0.29 | 5.19 ± 0.26 | 5.34 ± 0.20 | 0.06 | 0.02 | 0.58 |
| Delta-5 desaturase2 | 9.6 ± 0.6 | 9.0 ± 0.5 | 9.1 ± 0.6 | 8.9 ± 0.6 | 0.03 | 0.02 | 0.15 |
Effects of hypoxia and bed rest on glutathione redox capacity in erythrocytes (RBC) and in whole blood (WB).
| Ambulatory | Bed rest | ||||||
|---|---|---|---|---|---|---|---|
| Normoxia | Hypoxia | Normoxia | Hypoxia | Bed rest effect | Hypoxia effect | Interaction | |
| Hematocrit (percent) | 46 ± 1 | 51 ± 1 | 47 ± 1 | 51 ± 1 | 0.20 | <0.001 | 0.12 |
| Total glutathione (μmol/L RBC) | 2692 ± 84 | 2620 ± 79 | 2617 ± 105 | 2547 ± 86 | 0.07 | 0.21 | 0.34 |
| Total glutathione (μmol/L WB) | 1245 ± 49 | 1331 ± 52 | 1236 ± 54 | 1287 ± 51 | 0.22 | 0.01 | 0.45 |
| GSH/GSSG1 (ratio) | 137 ± 26 | 213 ± 34* | 207 ± 41 | 176 ± 36 | 0.93 | 0.52 | 0.02 |
| GSSG (μmol/L RBC) | 32 ± 9 | 19 ± 5* | 21 ± 5 | 38 ± 20 | 0.87 | 0.43 | 0.02 |
| GSSG (μmol/L WB) | 15 ± 4 | 9 ± 2 | 10 ± 2 | 19 ± 10 | 0.89 | 0.76 | 0.02 |
| Glutathione FSR2 (percent/day) | 25 ± 4 | 38 ± 6 | 35 ± 3 | 41 ± 3 | 0.09 | 0.03 | 0.21 |
| Glutathione ASR3 (μmol/day/L RBC) | 669 ± 122 | 990 ± 143 | 898 ± 82 | 1053 ± 88 | 0.10 | 0.02 | 0.19 |
| Glutathione ASR (μmol/day/L WB) | 306 ± 55 | 493 ± 69 | 420 ± 40 | 524 ± 41 | 0.23 | 0.02 | 0.27 |
| GCL-C4 (fraction of GAPDH5) | 0.63 ± 0.09 | 1.01 ± 0.25 | 0.64 ± 0.10 | 0.85 ± 0.14 | 0.96 | 0.03 | 0.91 |
| GCL-M6 (fraction of GAPDH) | 0.82 ± 0.15 | 1.29 ± 0.14 | 0.87 ± 0.13 | 1.05 ± 0.12 | 0.74 | 0.05 | 0.27 |
Effects of hypoxia and bed rest on selected amino acid concentrations in plasma and red blood cells.
| Ambulatory | Bed rest | ||||||
|---|---|---|---|---|---|---|---|
| Normoxia | Hypoxia | Normoxia | Normoxia | Bed rest effect | Hypoxia effect | Interaction | |
| Homocysteine (μmol × L-1) | 15.3 ± 1.7 | 17.0 ± 1.4 | 14.7 ± 1.4 | 16.2 ± 1.4 | 0.38 | 0.003 | 0.93 |
| Cysteine (μmol × L-1) | 294 ± 12 | 299 ± 11 | 277 ± 10 | 304 ± 11 | 0.45 | 0.005 | 0.27 |
| Glycine (μmol × L-1) | 172 ± 9 | 185 ± 10* | 196 ± 12 | 185 ± 12 | 0.04 | 0.78 | 0.01 |
| Glutamate (μmol × L-1) | 61 ± 4 | 69 ± 5 | 62 ± 3 | 67 ± 3 | 0.81 | 0.03 | 0.59 |
| Glutamine (μmol × L-1) | 541 ± 10 | 515 ± 9 | 552 ± 21 | 522 ± 7 | 0.55 | 0.01 | 0.86 |
| Pyroglutamic acida (μmol × L-1) | 1.02 ± 0.08 | 0.90 ± 0.06 | 1.01 ± 0.07 | 0.89 ± 0.06 | 0.85 | 0.04 | 0.86 |
| Cysteine (μmol × L-1) | 70 ± 3 | 79 ± 3 | 72 ± 4 | 70 ± 3 | 0.20 | 0.33 | 0.07 |
| Glycine (μmol × L-1) | 368 ± 11 | 389 ± 13 | 372 ± 12 | 393 ± 12 | 0.49 | <0.001 | 0.98 |
| Glutamate (μmol × L-1) | 477 ± 24 | 481 ± 18 | 448 ± 16 | 478 ± 17 | 0.33 | 0.16 | 0.37 |
| Glutamine (μmol × L-1) | 1053 ± 147 | 1015 ± 209 | 1042 ± 141 | 1000 ± 215 | 0.79 | 0.73 | 0.97 |